{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:13:10Z","timestamp":1779354790000,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Beijing Integrative Medicine Association Research Project","award":["No. ZHKY-2025-5193"],"award-info":[{"award-number":["No. ZHKY-2025-5193"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15996-2","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T02:06:04Z","timestamp":1775873164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of albumin-bound paclitaxel combined with anlotinib and immunotherapy in advanced non-small cell lung cancer with liver metastases: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hui","family":"Teng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"15996_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G, Reck M. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10:71.","journal-title":"Nat Rev Dis Primers"},{"key":"15996_CR2","doi-asserted-by":"publisher","first-page":"175883592412754","DOI":"10.1177\/17588359241275421","volume":"16","author":"J Zhao","year":"2024","unstructured":"Zhao J, Zhong J, Chen Y, Chen Z, Yin H, He Y, Chen R, Guo R. Molecular features of NSCLC patients with liver metastasis. Ther Adv Med Oncol. 2024;16:17588359241275421.","journal-title":"Ther Adv Med Oncol"},{"key":"15996_CR3","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/CM9.0000000000002981","volume":"137","author":"L Zhu","year":"2024","unstructured":"Zhu L, Yu X, Tang X, Hu C, Wu L, Liu Y, Zhou Q. Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer. Chin Med J (Engl). 2024;137:1019\u201332.","journal-title":"Chin Med J (Engl)"},{"key":"15996_CR4","doi-asserted-by":"publisher","first-page":"13443","DOI":"10.3390\/cimb46120802","volume":"46","author":"V \u0106eriman Krsti\u0107","year":"2024","unstructured":"\u0106eriman Krsti\u0107 V, Samard\u017ei\u0107 N, Gaji\u0107 M, Savi\u0107 M, \u0160eha B. Roksandi\u0107 Milenkovi\u0107 M and Jovanovi\u0107 D. Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases. Curr Issues Mol Biol. 2024;46:13443\u201355.","journal-title":"Curr Issues Mol Biol"},{"key":"15996_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404:803\u201322.","journal-title":"Lancet"},{"key":"15996_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30:219\u201335.","journal-title":"Ann Oncol"},{"key":"15996_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jtho.2020.11.007","volume":"16","author":"SK Padda","year":"2021","unstructured":"Padda SK, Reckamp KL. Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach. J Thorac Oncol. 2021;16:178\u201382.","journal-title":"J Thorac Oncol"},{"key":"15996_CR8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/CMAR.S472196","volume":"16","author":"X Li","year":"2024","unstructured":"Li X, Wu D, Tang J, Wu Y. The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1\/L1 Inhibitors in the 2(nd) or Above Line of Advanced NSCLC: A Retrospective Cohort Study. Cancer Manag Res. 2024;16:1003\u201312.","journal-title":"Cancer Manag Res"},{"key":"15996_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.4149\/neo_2024_240716N299","volume":"71","author":"X Li","year":"2024","unstructured":"Li X, Wu D, Tang J, Wu Y. Albumin bound-paclitaxel combined with anlotinib and immunotherapy in the second-line treatment of ES-SCLC: a retrospective cohort study. Neoplasma. 2024;71:482\u20139.","journal-title":"Neoplasma"},{"key":"15996_CR10","doi-asserted-by":"publisher","first-page":"105833","DOI":"10.1016\/j.esmoop.2025.105833","volume":"10","author":"IP da Silva","year":"2025","unstructured":"da Silva IP, Zimmer L, Blay JY, Maio M, Larkin J, Grimm MO, Puri S, Butler MO, Patel S, Thakkar PK, Long GV, Melero I. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. ESMO Open. 2025;10:105833.","journal-title":"ESMO Open"},{"key":"15996_CR11","doi-asserted-by":"publisher","first-page":"115381","DOI":"10.1016\/j.ejca.2025.115381","volume":"220","author":"JJ Luke","year":"2025","unstructured":"Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, Mackiewicz J, Merino LC, Chiarion-Sileni V, Kirkwood JM, Robert C, Schadendorf D, de Galitiis F, Carlino MS, Dummer R, Mohr P, Odeleye-Ajakaye A, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025;220:115381.","journal-title":"Eur J Cancer"},{"key":"15996_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41598-024-83947-7","volume":"15","author":"G Yin","year":"2025","unstructured":"Yin G, Liu X, Yu X, Tan S, Liu F. Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer. Sci Rep. 2025;15:30.","journal-title":"Sci Rep"},{"key":"15996_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen H, Mo H, Zhao N, Sun X, Liu B, Gao R, Xu B, Zhang Z, Liu Z, Ma F. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell. 2025;43:446\u2013e463447.","journal-title":"Cancer Cell"},{"key":"15996_CR14","doi-asserted-by":"publisher","first-page":"1539616","DOI":"10.3389\/fimmu.2025.1539616","volume":"16","author":"H Lan","year":"2025","unstructured":"Lan H, Liu H, Hou H, Zhang C, Zhu J, Zhou N, Zhang X. Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer. Front Immunol. 2025;16:1539616.","journal-title":"Front Immunol"},{"key":"15996_CR15","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.21037\/tlcr-21-197","volume":"10","author":"WM Brueckl","year":"2021","unstructured":"Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Transl Lung Cancer Res. 2021;10:3093\u2013105.","journal-title":"Transl Lung Cancer Res"},{"key":"15996_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, Stepan DE, Shumaker RC, Motzer RJ. Phase IB\/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020;38:1154\u201363.","journal-title":"J Clin Oncol"},{"key":"15996_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","volume":"18","author":"PL Su","year":"2025","unstructured":"Su PL, Furuya N, Asrar A, Rolfo C, Li Z, Carbone DP, He K. Recent advances in therapeutic strategies for non-small cell lung cancer. J Hematol Oncol. 2025;18:35.","journal-title":"J Hematol Oncol"},{"key":"15996_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41698-025-01261-5","volume":"10","author":"JU Lim","year":"2026","unstructured":"Lim JU, Lin HY, Kang L, Le H, Tang TY, Champiat S, Dumbrava EE, Le X, Naing A, Piha-Paul SA, Ahnert JR, Tsimberidou AM, Yap TA, Fu S, Meric-Bernstam F, Hong DS. Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson. NPJ Precis Oncol. 2026;10:59.","journal-title":"NPJ Precis Oncol"},{"key":"15996_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB. Pierce RH and Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017;5:417\u201324.","journal-title":"Cancer Immunol Res"},{"key":"15996_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21037\/tlcr-22-852","volume":"12","author":"CR Xu","year":"2023","unstructured":"Xu CR, Chen Q, Zhou C, Wu L, Li W, Zhang H, Li Y, Xu F, Xiong J, Wang Q, Zhang H, Jiang Y, Yin H, Wu Q, Dai Q, Hu J, Chen J, Zhang J, Wu G, Yin J, Zhao J, Liu B, Shan J, Sheng L, Chen Q, Han Z, Shi H, Liu Y, Chen J, Wu YL. Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV). Transl Lung Cancer Res. 2023;12:127\u201340.","journal-title":"Transl Lung Cancer Res"},{"key":"15996_CR21","doi-asserted-by":"publisher","unstructured":"Mucherino S, Lorenzoni V, Triulzi I, Del Re M, Orlando V, Capuano A, Danesi R, Turchetti G, Menditto E. Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review. Cancers (Basel). 2024;16. https:\/\/doi.org\/10.3390\/cancers16050995.","DOI":"10.3390\/cancers16050995"},{"key":"15996_CR22","first-page":"284","volume":"22","author":"K Ding","year":"2025","unstructured":"Ding K, Liu D, Li X, Peng Z, Zhu L, Xu Y. Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window. Cancer Biol Med. 2025;22:284\u201394.","journal-title":"Cancer Biol Med"},{"key":"15996_CR23","doi-asserted-by":"publisher","unstructured":"Livanou ME, Nikolaidou V, Skouras V, Fiste O, Kotteas E. Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse. Cancers (Basel). 2024;16. https:\/\/doi.org\/10.3390\/cancers16061196.","DOI":"10.3390\/cancers16061196"},{"key":"15996_CR24","doi-asserted-by":"publisher","first-page":"893716","DOI":"10.3389\/fonc.2022.893716","volume":"12","author":"Y Fang","year":"2022","unstructured":"Fang Y, Su C. Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases. Front Oncol. 2022;12:893716.","journal-title":"Front Oncol"},{"key":"15996_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27:152\u201364.","journal-title":"Nat Med"},{"key":"15996_CR26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.bulcan.2020.07.009","volume":"107","author":"E Gobbini","year":"2020","unstructured":"Gobbini E, Charles J, Toffart AC, Leccia MT, Moro-Sibilot D, Levra MG. Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients. Bull Cancer. 2020;107:1098\u2013107.","journal-title":"Bull Cancer"},{"key":"15996_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/1759-7714.15209","volume":"15","author":"G Lin","year":"2024","unstructured":"Lin G, Wang Z, Chu Q, Hu Y, Huang D, Wang J, Yang F, Zhong W, Zhou C, Zhu B, Ai X, Cao B, Cao Y, Chen M, Chen X, Chu T, Duan J, Fan Y, Fang Y, Feng S, Feng W, Guo H, Han C, He Y, Hong S, Hu J, Huang M, Huang Y, Jiang D, Jiang K, Jiang R, Jin B, Jin S, Li J, Li M, Li Z, Li C, Lin J, Liu A, Liu SM, Yutao L, Liu Z, Liu Z, Liu Z, Liu Z, Liu Z, Lu Y, Lv T, Ma Z, Miao Q, Peng M, Pu X, Ren XB, Shan J, Shan J, Shen P, Shen B, Shi M, Song Y, Song Z, Su C, Sun J, Tian P, Wang J, Wang F, Wang H, Wang J, Wang Q, Wang W, Wang Y, Wu L, Wu F, Xia Y, Xie C, Xie C, Xin T, Xiong J, Xu H, Xu S, Xu Y, Xu B, Xu C, Yan X, Yang Z, Yao W, Yu Y, Feng Y, Yu Z, Yu Y, Yue D, Zhang H, Zhang H, Zhang L, Zhang L, Zhang Q, Zhang T, Zhang B, Zhao J, Zhao M, Zheng X, Zhong Q, Zhou J, Zhou P, Zhu Z, Zou J, Zou Z. Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thorac Cancer. 2024;15:419\u201326.","journal-title":"Thorac Cancer"},{"key":"15996_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/1120009X.2024.2397924","volume":"37","author":"X Li","year":"2025","unstructured":"Li X, Peng Y, Wu D, Tang J, Wu Y. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy. J Chemother. 2025;37:527\u201335.","journal-title":"J Chemother"},{"key":"15996_CR29","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.2147\/CMAR.S539781","volume":"17","author":"D Wu","year":"2025","unstructured":"Wu D, Liu K, Peng Y, Liu Y, Tang J, Lin X, Li X. The Efficacy and Safety of Anlotinib Treatment for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Who Achieved Stable Disease (SD) After Two Cycles of First-Line Chemotherapy Combined with Immunotherapy: A Retrospective Cohort Study. Cancer Manag Res. 2025;17:2795\u2013805.","journal-title":"Cancer Manag Res"},{"key":"15996_CR30","doi-asserted-by":"publisher","first-page":"e70741","DOI":"10.1002\/cam4.70741","volume":"14","author":"A Mouri","year":"2025","unstructured":"Mouri A, Imai H, Endo S, Nakagawa J, Tsukamoto K, Kurata Y, Yamaguchi O, Masaki K, Hashimoto K, Shiono A, Miura Y, Kobayashi K, Kaira K, Kagamu H. A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab. Cancer Med. 2025;14:e70741.","journal-title":"Cancer Med"},{"key":"15996_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/ajco.12870","volume":"14","author":"D Wu","year":"2018","unstructured":"Wu D, Liang L, Nie L, Nie J, Dai L, Hu W, Zhang J, Chen X, Han J, Ma X, Tian G, Han S, Long J, Wang Y, Zhang Z, Xin T, Fang J. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. Asia Pac J Clin Oncol. 2018;14:446\u201352.","journal-title":"Asia Pac J Clin Oncol"},{"key":"15996_CR32","doi-asserted-by":"publisher","first-page":"e70449","DOI":"10.1002\/cam4.70449","volume":"13","author":"X Li","year":"2024","unstructured":"Li X, Wu D, Peng Y, Tang J, Wu Y. The Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Anlotinib and PD-1\/L1 Inhibitors For Treating Patients With Extensive-Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study. Cancer Med. 2024;13:e70449.","journal-title":"Cancer Med"},{"key":"15996_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","volume":"22","author":"Z Rahal","year":"2025","unstructured":"Rahal Z, El Darzi R, Moghaddam SJ, Cascone T, Kadara H. Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nat Rev Clin Oncol. 2025;22:463\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"15996_CR34","doi-asserted-by":"publisher","first-page":"286170","DOI":"10.1155\/2014\/286170","volume":"2014","author":"JY Li","year":"2014","unstructured":"Li JY, Duan XF, Wang LP, Xu YJ, Huang L, Zhang TF, Liu JY, Li F, Zhang Z, Yue DL, Wang F, Zhang B, Zhang Y. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res. 2014;2014:286170.","journal-title":"J Immunol Res"},{"key":"15996_CR35","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.21037\/jtd-23-387","volume":"15","author":"C Yin","year":"2023","unstructured":"Yin C, Zou GR, He Y, Li J, Yan HW, Su Z, Cao XL, Li XB. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study. J Thorac Dis. 2023;15:1838\u201347.","journal-title":"J Thorac Dis"},{"key":"15996_CR36","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.5306\/wjco.v16.i4.102199","volume":"16","author":"WM Liu","year":"2025","unstructured":"Liu WM, Liu YR, Peng Y, Tang J, Li XB. Combination of anlotinib and albumin-bound paclitaxel in 2(nd) line and above treatment of advanced gastric cancer: A retrospective study. World J Clin Oncol. 2025;16:102199.","journal-title":"World J Clin Oncol"},{"key":"15996_CR37","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E. Karumanchi D and Garassino MC. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024;42:2860\u201372.","journal-title":"J Clin Oncol"},{"key":"15996_CR38","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal JW, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022;40:2295\u2013306.","journal-title":"J Clin Oncol"},{"key":"15996_CR39","doi-asserted-by":"publisher","first-page":"e040691","DOI":"10.1136\/bmjopen-2020-040691","volume":"10","author":"Q Liu","year":"2020","unstructured":"Liu Q, Luo X, Peng L, Yi L, Wan X, Zeng X, Tan C. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 2020;10:e040691.","journal-title":"BMJ Open"},{"key":"15996_CR40","doi-asserted-by":"publisher","first-page":"2468070","DOI":"10.1080\/21645515.2025.2468070","volume":"21","author":"Q Cai","year":"2025","unstructured":"Cai Q, You S, Huang J, Gong C, Zhang W, Zhou A. Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer. Hum Vaccin Immunother. 2025;21:2468070.","journal-title":"Hum Vaccin Immunother"},{"key":"15996_CR41","doi-asserted-by":"publisher","unstructured":"Xie M, Li N, Xu X, Xu Y, Li H, Zhu L, Sheng J, Zhou Z, Fan Y. The Efficacy of PD-1\/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14174333.","DOI":"10.3390\/cancers14174333"},{"key":"15996_CR42","doi-asserted-by":"publisher","first-page":"1684759","DOI":"10.3389\/fimmu.2025.1684759","volume":"16","author":"L Sun","year":"2025","unstructured":"Sun L, Chen B, Wang B, Li J, Li L, Tian C, Zhang H, Liu P, Liu X. Combination immunotherapy and anti-angiogenic therapy shows promising efficacy in NSCLC patients with recurrent or refractory brain metastases and negative driver genes. Front Immunol. 2025;16:1684759.","journal-title":"Front Immunol"},{"key":"15996_CR43","doi-asserted-by":"publisher","first-page":"101200","DOI":"10.1016\/j.currproblcancer.2025.101200","volume":"56","author":"Y Yamaguchi","year":"2025","unstructured":"Yamaguchi Y, Shinno Y, Masuda K, Ariyasu R, Nosaki K, Hakozaki T, Tokito T, Nomura S, Nishio M, Goto K, Hosomi Y, Azuma K, Ohe Y. Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure. Curr Probl Cancer. 2025;56:101200.","journal-title":"Curr Probl Cancer"},{"key":"15996_CR44","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1186\/s12885-025-14712-w","volume":"25","author":"W Zhao","year":"2025","unstructured":"Zhao W, Li B, Gu Y, Jin X, Li Z, Guo W, Lu X, Jiang J. The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis. BMC Cancer. 2025;25:1332.","journal-title":"BMC Cancer"},{"key":"15996_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.bjc.6602934","volume":"94","author":"K Hiraoka","year":"2006","unstructured":"Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8\u2009+\u2009T cells and CD4\u2009+\u2009T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94:275\u201380.","journal-title":"Br J Cancer"},{"key":"15996_CR46","doi-asserted-by":"publisher","first-page":"106460","DOI":"10.1016\/j.compbiomed.2022.106460","volume":"152","author":"J Zhang","year":"2023","unstructured":"Zhang J, Liu X, Huang Z, Wu C, Zhang F, Han A, Stalin A, Lu S, Guo S, Huang J, Liu P, Shi R, Zhai Y, Chen M, Zhou W, Bai M, Wu J. T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing. Comput Biol Med. 2023;152:106460.","journal-title":"Comput Biol Med"},{"key":"15996_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","volume":"10","author":"Q Huang","year":"2025","unstructured":"Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, Li X, Dong S, Dong Z, Hu S. Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduct Target Ther. 2025;10:186.","journal-title":"Signal Transduct Target Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15996-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15996-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15996-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:04:09Z","timestamp":1779354249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15996-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15996"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15996-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors bear full responsibility for ensuring the accuracy and integrity of all aspects of the study. Any queries regarding the precision or honesty of any part of the work were duly investigated and addressed. The study adhered to the principles outlined in the Declaration of Helsinki (revised in 2013). Approval for this retrospective trial was obtained from the Ethics Committee of Hubei Cancer Hospital Affiliated with Tongji Medical College (Wuhan, China) (Approval No. HBCHEC2021099). informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"653"}}